ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-bromo-2-methoxyphenyl)-1H-pyrrole-3-carboxylate | 1403680-01-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-bromo-2-methoxyphenyl)-1H-pyrrole-3-carboxylate
• CAS: 1403680-01-2
• 化学式: C₁₈H₁₇BrN₄O₃
• 分子量: 417.262
• InChiKey: BJADEAMPZAVOCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS<br/>[FR] PYRIMIDINYLPYRROLES SUBSTITUÉS ACTIFS EN TANT QU'INHIBITEURS DE KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2012143248A1

  公开（公告）日：2012-10-26

  The present invention relates to substituted pyrimidinyl-pyrrole compounds of formula (I) which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Janus kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

  本发明涉及式(I)的取代嘧啶基-吡咯烷化合物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病方面具有用处，特别是Janus激酶。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。
• SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS
  申请人：Brasca Maria Gabriella

  公开号：US20140155421A1

  公开（公告）日：2014-06-05

  The present invention relates to substituted pyrimidinyl-pyrrole compounds of formula (I) which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Janus kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

  本发明涉及式（I）的取代嘧啶基-吡咯化合物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病，特别是Janus激酶方面具有用处。本发明还提供了制备这些化合物的方法，包括这些化合物的制药组合物，以及利用这些化合物或含有它们的制药组合物治疗疾病的方法。
• Segmented Degradable Polymers and Conjugates Made Therefrom
  申请人：Nektar Therapeutics

  公开号：US20130072709A1

  公开（公告）日：2013-03-21

  The present invention provides, among other things, segmented, degradable polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains divided or separated by one or more degradable linkages into polymer segments having a molecular weight suitable for renal clearance. The polymeric reagents can have a substantially linear structure, a branched structure, or a multiarm structure. Each structure includes one or more linkages capable of degradation in vivo.
• METHODS AND COMPOSITIONS FOR TYPING MOLECULAR SUBGROUPS OF MEDULLOBLASTOMA
  申请人：Ellison David

  公开号：US20140155400A1

  公开（公告）日：2014-06-05

  Immunohistochemical methods and compositions for the typing of molecular subgroups of medulloblastomas are provided. The methods comprise determining a protein expression profile for a sample obtained from a medulloblastoma by detecting expression of GAB 1, filamin A, or at least two biomarker proteins selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and typing the medulloblastoma as a WNT pathway tumor, a SHH pathway tumor, or a non-WNT/non-SHH tumor based on this protein expression profile. Kits for typing a medulloblastoma according to these three molecular subgroups are provided. The kits comprise at least two antibodies, wherein each of said antibodies specifically binds to a distinct biomarker protein selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and can optionally comprise one or more of instructions for use, reagents for detecting antibody binding to one or more of said biomarker proteins, and one or more positive control samples.
• US9005907B2
  申请人：——

  公开号：US9005907B2

  公开（公告）日：2015-04-14